Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

Fig. 1

Study algorithm of the PRE-PREVENCYS trial with expected distribution of patients. BME: bimanual examination; CRE: clinical response evaluation; CT: computed tomography; ddMVAC: dose-dense Methotrexate, Vinblastine, Adriamycin and Cisplatin; ePLND: extended pelvic lymph node dissection; FDG: 18F-fluoro-2-deoxy-D-glucose; Gem/Cis: Gemcitabine/Cisplatin; NAC: neoadjuvant chemotherapy; PET: positron-emission tomography; RC: radical cystectomy; TUR: transurethral resection

Back to article page